

THE OREGON DEPARTMENT OF HUMAN SERVICES

HEALTH SERVICES – OREGON MEDICAL MARIJUANA PROGRAM

In the Matter of the Petition of Edward Glick,)

#

to add Clinical Depression, Depressive)
Symptoms, Post-Traumatic Stress Disorder) EDWARD GLICK’S PETITION
(PTSD), Severe Anxiety, Agitation and) PURSUANT TO ORS §475.334
Insomnia, to Those Diseases and Conditions)
Which Qualify as ‘Debilitating Medical)
Conditions’ under the Oregon Medical)
Marijuana Act)

TO: Grant Higginson, MD, MPH, Administrator, Office of Community Health and Health Planning

Petitioner Edward Glick, petitions the Oregon Medical Marijuana Program to add Clinical Depression, Depressive Symptoms, Post-Traumatic Stress Disorder (PTSD), Severe Anxiety, Agitation and Insomnia to Those Diseases and Conditions Which Qualify as ‘Debilitating Medical Conditions’ under the Oregon Medical Marijuana Act, as follows:

1.

Petitioner Edward Glick, is a person authorized to bring this petition. Petitioner’s interest derives from a survey petitioner conducted at the Eugene Compassion Center.

2.

This petition is subject to OAR 333-008-0090, and for that reason, petitioner submits the following new scientific research in support of adding each of these conditions. Copies of the research will be provided at a later time in electronic format on a CD.

PROPOSED CONDITION	NEW SCIENTIFIC RESEARCH
--------------------	-------------------------

Clinical Depression and Depressive Symptoms

Depression/Depressive Symptoms Research Studies

Hungund B. L, et. al., Upregulation of CB-1 receptors and agonist-stimulated[35S]GTPyS binding in the prefrontal cortex of depressed suicide victims. *Molecular Psychiatry* 9 184-190. (2004).

Jiang, W., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. *J. Clin. Invest* 115:3104-3116(2005).

Degenhardt, L., et. al., Exploring the association between cannabis use and depression. *Addiction* 98 1493-1504.(2004).

Hill, M., Gorzalka, B., Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? *Behavioral Pharmacology* 16:333-352 (2005).

Vinod, K., Hungund, B., Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disorders. *Life Sciences* 77: 1560-1583. (2005).

Barrero, F., Morales, B., et al., Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). *The Pharmacogenomics Journal* 5: 135-141 (2005).

Witkin, J., Tzavara, E., et al., A therapeutic role for cannabinoid CB 1 receptor antagonists in major depressive disorders. *TRENDS in Pharmacological Sciences* Vol. 26 No. 12 (2005).

Amatmann D., et. al., Survey of cannabis use in patients with amyotrophic lateral sclerosis. *American Journal of Hospice and Palliative Medicine* 21, No. 2:95-104. (2004).

Gobbi, G., Bambico, F. R., et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockage of anandamide hydrolysis. *The National Academy of Sciences- USA* . (2005).

<p>Post-Traumatic Stress Disorder (PTSD)</p>	<p><u>Post Traumatic Stress Disorder Patient Surveys</u></p> <p>Three OMMP PTSD Cannabis Use Surveys</p> <p><u>Personal Correspondence</u></p> <p>H. E.</p>
---	---

Severe Anxiety

Severe Anxiety Research Studies

Di Marzo, V. et. al., The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology 480: 133-1150. (2003).

Di Marzo, V. et. al., The cannabinoid system and its Therapeutic Exploitation. ResearchReview. (Unknown date).

Patel, S., et. al., Pharmacological Evaluation of Cannabinoid Receptor Ligands in a Mouse Model of Anxiety: Further Evidence for an Anxiolytic Role for Endogenous Cannabinoid Signaling . The Journal of Pharmacology and Experimental Therapeutics Vol.318,No.1 (2006)

Rutkowska, M., et. al., Effects of cannabinoids on the anxiety-like response in mice Pharmacological Reports 58, 200-206, (2006).

Zarudi, A., et al., Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Jpurnal of Medical and Biological Research 39: 421-429. (2006).

Research Abstracts

Musty, R., et al., Potential Therapeutic effects of Cannabinoids on Anxiety, a review. IACMpresentation. (2005).

Holdcroft, A. et al., Qualitative measures of mood and sensory responses to cannabisextract (Cannador) in the Canpop study. IACM presentation. (Unknown date).

Conference Abstracts/ Press Releases

Cannabinoids demonsrrate novel modes of action and responses to stress. 2005 APSCConference.

Articles

Marshall, J., Drugs Inspired by a Drug. Science, Vol. 311. Jan. 20, 2006.

Agitation

Agitation Research Studies

Urigen, L. et. al., Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB-1 receptors. *Neuropharmacology* 46: 966-973. (2004).

Young, H., Cannabinoids in Bipolar Affective Disorder. Ongoing study, University of British Columbia.

Research Reviews

Ashton, C., et al., Cannabinoids in Bipolar affective disorder: a review and discussion of their therapeutic potential. *Journal of Psychopharmacology* 19: 293-300. (2005).

Grinspoon, L., The Use of Cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. *J. Psychoactive Drugs*. 30(2):171-177

Conference Abstracts

Leweke, F., et. al., Cannabidiol as an antipsychotic. A double-blind controlled clinical trial on Cannabidiol vs. Amisulpride in acute schizophrenia. IACM. (2005).

Press Releases

BBC News- U.K.. Cannabis May Help Mentally Ill. (2005).

Personal Correspondence

M. Tina, Bipolar and Medicinal Marijuana. (2006)

Insomnia

Insomnia Research Studies

Rodriguez, E., et. al., Anandamide Enhances Extracellular Levels of Adenosine and Induces Sleep: An In Vivo Microdialysis Study. *Sleep* 26, Number 8: 943-947. (2003).

Rodriguez, E., et. al., Cannabidiol, a constituent of *Cannabis sativa*, modulates sleep in rats *FEBS Letters* 580 4337–4345 (2006)

Zarudi, A., History of cannabis as a medicine: a review. *Rev Bras Psiquiatr.* ;28(2):153-7 (2006).

Nicholson, A., et. al. Effect of Delta-9 Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults. *J. Clinical Psychopharmacology* Vol. 24, Number 3, June 2004

Abstracts

Carley, DW, Functional role for cannabinoids in respiratory stability during sleep. *Sleep*, 15:25(4): 399-400 (2002).

Conference Presentations

Angelucci, L., et.al., Preliminary data from an ongoing survey on the therapeutic use of cannabis in Italy. IACM Conference (2005).

Mikuriya, T., ICD-9 cm Codes for Neuropsychiatric conditions encountered 1990-2005.

Eubanks, L., et al, A molecular Link between the Active Component of Marijuana and Alzheimers Disease Pathology. *Molecular Pharmaceutics* Vol XXXX, No. XXXX (2006).

Fowler, C., The cannabinoid system and its pharmacological manipulation- a review, with emphasis upon the uptake and hydrolysis of anandamide. *Fundamental and Clinical Pharmacology* 20 549-562, (2006).

Non-specific research

3.

Petitioner reserves the right to supplement this petition with additional references to new scientific research, as they become known to petitioner and to present them to the panel, at the time of petitioner's testimony.

WHEREFORE, Petitioner requests, pursuant to OAR 333-008-0090(4), that the Department appoint an expert panel consistent with the attached agreed upon policies and procedures and, as required by ORS §475.334 and OAR 333-008-0090(6), make a final decision regarding this petition within 180 days of the Department's receipt of the petition.

Respectfully submitted _____ day of January, 2009.

Edward Glick, Petitioner